Remove FDA Approval Remove Genetic Engineering Remove In-Vivo
article thumbnail

Spotlighting Lupus Awareness Month: CAR-T Technology Creates New Avenues for Treatment of a Devastating Disease

WCG Clinical

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. In these cases B cell depletion is a feature, not a bug.

In-Vivo 40
article thumbnail

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL.

Protein 98